
Instil Bio (TIL) Stock Forecast & Price Target
Instil Bio (TIL) Analyst Ratings
Bulls say
Instil Bio Inc., as a clinical-stage biopharmaceutical company, is advancing its innovative cell therapy pipeline focused on autologous tumor infiltrating lymphocyte (TIL) therapies, which hold promise for treating various solid tumors, including ovarian and renal cancers. The development of ITIL-306, featuring a CoStAR molecule that targets tumor-associated antigens, signifies a strategic position in the evolving oncology landscape, potentially driving growth. As investor confidence strengthens in the oncology sector, there is potential for broader positive implications for Instil Bio's TIL therapies, particularly as preclinical results and upcoming trials continue to validate their efficacy within the biopharmaceutical marketplace.
Bears say
Instil Bio Inc faces significant challenges in advancing its clinical-stage cell therapy candidates, highlighted by concerns over delays in clinical assessments and the potential for unfavorable clinical outcomes, particularly with the AXN-2510 therapy in non-small cell lung cancer and small cell lung cancer. The observation of similar overall survival (OS) curves before and after recent updates has led to skepticism among bearish investors, emphasizing a perceived lack of meaningful progress. Additionally, there is an ongoing risk of dilution in the medium to long term, which could further impact investor sentiment and stock performance.
This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.
Instil Bio (TIL) Analyst Forecast & Price Prediction
Start investing in Instil Bio (TIL)
Order type
Buy in
Order amount
Est. shares
0 shares